Justin Walsh

Stock Analyst at Jones Trading

(0)
# 3453
Out of 5,218 analysts
37
Total ratings
30.77%
Success rate
0.85%
Average return
21 Stocks
Name Action Price Target Current % Upside Ratings Updated
Rapport Therapeutics
Initiates Coverage On: Buy
42
18.84 122.93% 1 Oct 18, 2024
Theratechnologies
Downgrades: Hold
n/a
n/a n/a 2 Oct 11, 2024
BioLine Rx
Initiates Coverage On: Buy
2
0.23 769.57% 1 Sep 4, 2024
Lantheus Holdings
Maintains: Strong Buy
105 146
93.11 56.8% 7 Jul 25, 2024
Y-mAbs Therapeutics
Initiates Coverage On: Buy
23
9.37 145.46% 1 Jul 11, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
15 22
3.45 537.68% 2 May 16, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
16
3.93 307.12% 1 May 10, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
20
4.09 389% 1 Apr 17, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
n/a
n/a n/a 2 Mar 20, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
n/a
n/a n/a 2 Oct 4, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reinstates: Buy
4
1.06 277.36% 4 Sep 7, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
20
2.9 589.66% 1 Sep 6, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
18
0.98 1736.73% 2 May 16, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
4 1
n/a n/a 2 May 11, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
175
0.07 249900% 1 Mar 22, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
440
5.28 8233.33% 1 Feb 10, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
75
1.25 5900% 1 Oct 7, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
17 20
35.43 -43.55% 1 May 20, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
440 200
3.6 5455.56% 2 Apr 5, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
10
1.46 584.93% 1 Jan 19, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
800
3.12 25541.03% 1 Sep 2, 2021